MATERIALS AND METHODS: After institutional review board approval and informed consent taken from all the patients, 40 patients with prostate cancer were included in this research. Two readers independently evaluated the results of T1W, T2W, DCE T1W, and DWI-ADC mapping sequences and proton H-MRS for the depiction of prostate cancer. Reference standard was the transrectal ultrasonography-guided biopsy and the surgical histopathological results. Statistical analysis was assessed by the Fisher exact t test, Wilcoxon signed rank test, variance analysis test with kappa (κ) values and receiver operating characteristics (ROC) curve for ADC values, choline (Cho)/citrate (Cit) and Cho+creatine (Cre)/Cit ratios for each observer.
RESULTS: Based on both readers' results, sensitivity declined to 31% and specificity to 75% for the T1W sequence, sensitivity declined to 43% and specificity to 67% for the DCE T1W sequence, sensitivity declined to 46% and specificity to 68% for the T2W sequence, sensitivity declined to 29% and specificity to 82% for the DWI-ADC mapping; and specificity was 49% for the Cho/Cit and Cho+Cre/Cit ratios, sensitivity was 69% for the Cho/Cit ratio, and sensitivity was 70% for the Cho+Cre/Cit ratio for H-MRS. The T2W sequence and H-MRS presented significant statistical differences for the depiction of prostatic cancer (P < 0.05), the most efficient sequence to detect prostatic cancer was H-MRS: Cho+Cre/Cit and Cho/Cit ratios.
CONCLUSION: Instead of using either sequences alone owing to low sensitivity and specificity rates, combined use of MRI techniques could easily improve the detection and staging of prostate cancer.
Written by:
Aydn H, Kzlgöz V, Tatar IG, Damar C, Ugan AR, Paker I, Hekimoğlu B. Are you the author?
*Radiology Department, Urology Department, and Pathology Department, Dışkapı Yıldırım Beyazıt Education and Research Hospital; and Urology Department, Ankara Ulus Devlet Hastanesi, Ankara, Turkey.
Reference: J Comput Assist Tomogr. 2012 Jan;36(1):30-45.
doi: 10.1097/RCT.0b013e31823f6263
PubMed Abstract
PMID: 22261768
UroToday.com Prostate Cancer Section
